Ovarian suppression with a gonadotropin-releasing hormone agonist does not alter insulin-stimulated glucose disposal

被引:10
|
作者
Cooper, Brian C.
Sites, Cynthia K.
Casson, Peter R.
Toth, Michael J.
机构
[1] Univ Vermont, Dept Obstet & Gynecol, Burlington, VT 05405 USA
[2] Univ Vermont, Dept Med, Burlington, VT 05405 USA
关键词
ovarian hormones; estrogen; insulin sensitivity; GnRH agonist;
D O I
10.1016/j.fertnstert.2006.11.045
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Aging is associated with reduced tissue sensitivity to insulin. In women, these age-related changes may be accelerated by menopause. The effect of ovarian hormone deficiency on tissue insulin sensitivity in humans, however, has not been defined clearly. Thus, the goal of this study was to evaluate the effect of suppression of endogenous ovarian hormone production on insulin-stimulated glucose disposal. Design: Randomized, single-blind, placebo-controlled trial. Setting: General clinical research center. Patients: Thirteen healthy, nonobese premenopausal women. Intervention(s): Insulin-stimulated glucose disposal was determined by hyperinsulinemic (40 mU/m(2)/min) clamp during the early to midfollicular and midluteal phase of the menstrual cycle. Volunteers then received 2 months of treatment with the GnRH agonist (GnRHa) leuprolide acetate (n = 6) or placebo (n = 7) and were retested. Main Outcome Measure(s): Total, oxidative, and nonoxidative insulin-stimulated glucose disposal. Result(s): Because no effect of cycle phase was found on total, oxidative, or nonoxidative glucose disposal, pretreatment follicular and luteal phase values were averaged. Treatment with GnRHa had no effect on total glucose disposal (GnRHa: 1.0.6 +/- 0.9 to 10.8 +/- 0.9 vs. placebo: 10.2 +/- 0.7 to 10.4 +/- 1.0 mg/kg fat-free mass/min, P = .99). Similarly, there was no effect of GnRHa administration on oxidative (GnRHa: 2.77 +/- 0.58 to 3.89 +/- 0.58 vs. placebo: 2.74 +/- 0.42 to 3.33 +/- 0.62 mg/kg fat-free mass/min, P = .52; n = 6 and 6, respectively) or nonoxidative (GnRHa: 7.82 +/- 0.68 to 6.91 +/- 0.66 vs. placebo: 7.94 +/- 0.72 to 7.79 +/- 0.99 mg/kg fat-free mass/min, P = .59; n = 6 and 6, respectively) components of glucose disposal. Conclusion(s): Our results suggest that endogenous ovarian hormones do not regulate tissue responsiveness to insulin or intracellular pathways of glucose disposal.
引用
收藏
页码:1131 / 1138
页数:8
相关论文
共 50 条
  • [1] Ovarian suppression with gonadotropin-releasing hormone agonist reduces whole body protein turnover in women
    Toth, Michael J.
    Sites, Cynthia K.
    Matthews, Dwight E.
    Casson, Peter R.
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2006, 291 (03): : E483 - E490
  • [2] Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger
    Fatemi, Human Mousavi
    Garcia-Velasco, Juan
    FERTILITY AND STERILITY, 2015, 103 (04) : 870 - 873
  • [3] Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist
    Ozcelik, Bulent
    Turkyilmaz, Cagdas
    Ozgun, Mahmut Tuncay
    Serin, Ibrahim Serdar
    Batukan, Cem
    Ozdamar, Saim
    Ozturk, Ahmet
    FERTILITY AND STERILITY, 2010, 93 (05) : 1609 - 1614
  • [4] Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome
    Kol, S
    FERTILITY AND STERILITY, 2004, 81 (01) : 1 - 5
  • [5] Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells
    Tsui, Kuan-Hao
    Lee, Wen-Ling
    Seow, Kok-Min
    Yang, Lin-Wei
    Wang, Shih-Yi
    Wang, Peng-Hui
    Chang, Chi-Lun
    Yen, Ming-Shyen
    Cheng, Jiin-Tsuey
    Chen, Chih-Ping
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2014, 53 (01): : 35 - 42
  • [6] Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review
    Poggio, Francesca
    Lambertini, Matteo
    Bighin, Claudia
    Conte, Benedetta
    Blondeaux, Eva
    D'Alonzo, Alessia
    Dellepiane, Chiara
    Buzzatti, Giulia
    Molinelli, Chiara
    Boccardo, Francesco
    Del Mastro, Lucia
    CLINICAL MEDICINE INSIGHTS-REPRODUCTIVE HEALTH, 2019, 13
  • [7] Effects of a gonadotropin-releasing hormone agonist on rat ovarian adenocarcinoma cell lines in vitro and in vivo
    Maruuchi, T
    Sugiyama, T
    Kataoka, A
    Nishida, T
    Yakushiji, M
    JAPANESE JOURNAL OF CANCER RESEARCH, 1998, 89 (09): : 977 - 983
  • [8] Gonadotropin-releasing hormone agonist (GnRHa) trigger - State of the art
    Dosouto, Carlos
    Haahr, Thor
    Humaidan, Peter
    REPRODUCTIVE BIOLOGY, 2017, 17 (01) : 1 - 8
  • [9] Prevention of osteopenia induced with a gonadotropin-releasing hormone agonist in rats
    Sakamoto, S
    Sassa, S
    Mitamura, T
    Kudo, H
    Suzuki, S
    Yoshimura, S
    Zhou, YF
    Kikuchi, T
    Shinoda, H
    CALCIFIED TISSUE INTERNATIONAL, 1999, 65 (02) : 152 - 155
  • [10] Effects of gonadotropin-releasing hormone agonist and antagonist on ovarian activity in a mouse model for polycystic ovary
    Singh, Padmasana
    Srivastava, Raj Kamal
    Krishna, Amitabh
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2016, 163 : 35 - 44